The search strategy targeted studies involving GLP-1 receptor agonists (e.g., exenatide, liraglutide, dulaglutide, lixisenatide, benaglutide, loxenatide, semaglutide) and multi-target receptor agonists (e.g., tirzepatide), focusing on gastrointestinal adverse events (e.g., nausea, vomiting, diarrhea, constipation, dyspepsia, and reduced appetite) in patients with type 2 diabetes mellitus (T2DM) (Supplementary Material)
Inflammationpresence of mononuclear, polymorphonuclear, or connective tissue cells will be present in inflammation
45 MayoK
Peptide Half-Life Explained How to Reconstitute Peptides Cardiac Energy & Performance Tirzepatide Retatrutide vs Tirzepatide Retatrutide Next-Generation Atlanta Advanced Ready to source lab-grade peptides for your research